Survodutide (BI 456906)
Investigational dual GLP-1 / glucagon receptor co-agonist from Boehringer Ingelheim and Zealand Pharma.
At a glance
What it is: Investigational dual GLP-1 / glucagon receptor co-agonist from Boehringer Ingelheim and Zealand Pharma..
Primary research applications:
- Obesity (Phase 3)
- MASH (metabolic dysfunction-associated steatohepatitis)
- Type 2 diabetes
Editorial summary: Survodutide is one of the leading dual-receptor incretin / glucagon co-agonists in development. Phase 2 weight loss approached 19% at 46 weeks, and a positive Phase 2 MASH readout has positioned it as a top liver-focused candidate alongside its weight-loss program.
- Class / structure
- Synthetic peptide co-agonist; GLP-1 and glucagon receptor activity
- Half-life
- Designed for once-weekly dosing
- First described
- 2020s (Zealand / Boehringer Ingelheim)
- Regulatory status
- Investigational — Phase 3
What is Survodutide?
Survodutide is an investigational peptide co-agonist activating both the GLP-1 receptor (driving appetite suppression and glycemic effects) and the glucagon receptor (driving energy expenditure and lipid mobilization).
Discovery and development
Survodutide was originally discovered at Zealand Pharma and is being co-developed with Boehringer Ingelheim. It was designed as a balanced dual GLP-1 / glucagon receptor co-agonist — adding glucagon-driven energy expenditure to the GLP-1 appetite suppression mechanism, similar in concept to retatrutide but without GIP activity.
Mechanism of action
The dual-agonist concept asks the glucagon-receptor arm to balance glucose tolerability against the appetite-suppressing GLP-1 arm. Engineered receptor selectivity ratios produce net glycemic benefit while retaining the metabolic-rate effects of glucagon.[1]
Pharmacokinetics
Designed for once-weekly subcutaneous dosing, survodutide's pharmacokinetic profile in early-phase studies has been compatible with extended-interval dosing.
What the research shows
The peer-reviewed literature on Survodutide is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).
Claims and the evidence behind them
This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.
| Claim | What the evidence shows | Verdict |
|---|---|---|
| Produces ~19% weight loss at 46 weeks (Phase 2) | Le Roux 2024 | Promising |
| Improves MASH histology | Phase 2 readout | Promising |
| Will be FDA-approved by 2026 | Phase 3 ongoing; speculative | Uncertain |
Reported user experiences
How the research describes administration
Phase 2/3 trials use weekly subcutaneous injection with stepped dose escalation, similar in pattern to other incretin co-agonists.
Editorial note
Administration details above describe how the peptide is given in published studies. We summarize this for educational completeness — these descriptions are not protocols, dosing recommendations, or instructions for personal use. Decisions about treatment require an appropriately licensed clinician.
Safety considerations and open questions
The takeaway
Survodutide is a leading next-generation incretin program with a particularly strong narrative for liver disease. Phase 3 obesity and MASH readouts will determine whether it joins tirzepatide and retatrutide on the marketed-leadership tier or becomes a distinctive niche option for cardiometabolic-hepatic disease.
Frequently asked questions
Is survodutide FDA-approved?
No. As of 2026 it is an investigational drug in Phase 3 trials.
How does survodutide differ from retatrutide?
Retatrutide is a triple agonist (GLP-1 / GIP / glucagon). Survodutide is a dual agonist (GLP-1 / glucagon). Both add the energy-expenditure component via glucagon agonism.
References
- Zimmermann T, et al. Survodutide is a dual amylin- and glucagon-like peptide-1 receptor agonist with anti-obesity activity in preclinical models. Cell Rep Med. 2022;3(11):100815. https://pubmed.ncbi.nlm.nih.gov/36384096/
- Le Roux CW, et al. Survodutide for the Treatment of Obesity. N Engl J Med. 2024;390(15):1394-1407. https://pubmed.ncbi.nlm.nih.gov/38875354/